News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
744,353 Results
Type
Article (53063)
Company Profile (492)
Press Release (690798)
Section
Business (216614)
Career Advice (2842)
Deals (37182)
Drug Delivery (114)
Drug Development (86564)
Employer Resources (180)
FDA (17028)
Job Trends (15858)
News (367609)
Policy (35437)
Tag
Academia (2892)
Alliances (52879)
Alzheimer's disease (1354)
Approvals (16964)
Artificial intelligence (163)
Bankruptcy (379)
Best Places to Work (12224)
Biotechnology (366)
Breast cancer (199)
Cancer (1453)
Cardiovascular disease (123)
Career advice (2380)
CAR-T (103)
Cell therapy (311)
Clinical research (68922)
Collaboration (521)
Compensation (265)
COVID-19 (2760)
C-suite (120)
Data (1426)
Diabetes (187)
Diagnostics (6524)
Earnings (87502)
Employer resources (157)
Events (118113)
Executive appointments (412)
FDA (17737)
Funding (450)
Gene therapy (220)
GLP-1 (692)
Government (4782)
Healthcare (20056)
Infectious disease (2857)
Inflammatory bowel disease (124)
Interviews (550)
IPO (16930)
Job creations (4073)
Job search strategy (1970)
Layoffs (473)
Legal (8671)
Lung cancer (215)
Manufacturing (227)
Medical device (13887)
Medtech (13892)
Mergers & acquisitions (20392)
Metabolic disorders (513)
Neuroscience (1708)
NextGen Class of 2024 (7221)
Non-profit (4885)
Northern California (1736)
Obesity (291)
Opinion (232)
Patents (125)
People (61416)
Phase I (21449)
Phase II (30261)
Phase III (22559)
Pipeline (527)
Postmarket research (2928)
Preclinical (9240)
Radiopharmaceuticals (254)
Rare diseases (286)
Real estate (6405)
Regulatory (23552)
Research institute (2571)
Resumes & cover letters (453)
Southern California (1501)
Startups (3893)
United States (15902)
Vaccines (635)
Weight loss (224)
Date
Today (38)
Last 7 days (610)
Last 30 days (2400)
Last 365 days (37077)
2024 (36910)
2023 (41873)
2022 (53194)
2021 (57849)
2020 (56589)
2019 (49823)
2018 (37675)
2017 (34680)
2016 (34495)
2015 (40593)
2014 (34629)
2013 (29927)
2012 (31959)
2011 (32437)
2010 (30693)
Location
Africa (909)
Arizona (210)
Asia (42136)
Australia (7648)
California (3968)
Canada (1470)
China (316)
Colorado (177)
Connecticut (189)
Europe (94031)
Florida (544)
Georgia (138)
Illinois (425)
Indiana (234)
Maryland (668)
Massachusetts (3123)
Michigan (181)
Minnesota (305)
New Jersey (1138)
New York (1115)
North Carolina (837)
Northern California (1736)
Ohio (150)
Pennsylvania (941)
South America (1288)
Southern California (1501)
Texas (570)
Utah (113)
Washington State (421)
744,353 Results for "ebb therapeutics formerly known as cereve inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
November 11, 2024
·
4 min read
Press Releases
Sarah Sheikh Joins Cerevance’s Board of Directors
October 18, 2024
·
3 min read
Genetown
Cerevance Presents at The Federation of European Neuroscience Societies (FENS) Forum 2024
Cerevance will deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.
June 18, 2024
·
2 min read
Press Releases
Cerevance Achieves Second Milestone in Research Collaboration with Merck
October 8, 2024
·
2 min read
Genetown
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 Inhibitor Suitable for Clinical Assessment”.
April 22, 2024
·
3 min read
Genetown
Cerevance to Participate at Upcoming Investor Conferences
Cerevance today announced that company management will participate in the following investor conferences: Wells Fargo Virtual Private Biotech Symposium, May 6, 2024.
April 29, 2024
·
2 min read
Genetown
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, will present an oral presentation at the upcoming International Association of Parkinsonism and Related Disorders XXIX World Congress on Parkinson’s Disease and Related Disorders, taking place in Lisbon, Portugal from May 19-22, 2024.
May 9, 2024
·
2 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Press Releases
Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease
November 18, 2024
·
4 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
1 of 74,436
Next
